Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations

doi:10.5306/wjco.v2.i5.195

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6650)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series.

Item

Count

PDF

532

HTML

5734

Figures (1-5)

384

Sum=6650

May 10, 2011 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Clin Oncol. May 10, 2011; 2(5): 195-202
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.195

Full Size Figure Download Figure

Figure 2 Cell differentiation program in the pancreas. PDX1 and Ptf1a genes are expressed on E8.5-9.5 d, which determines the cell fate in the pancreas epithelium. By using the PDX1 or Ptf1a gene promoter-induced Cre-loxP system, all three lineages (islet, acini and duct) have the designed genetic alterations. The cell of origin of pancreatic ductal adenocarcinoma (PDAC) is still under discussion. Experimentally, PDAC can be derived from all three lineages.

Citation: Ijichi H. Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 195-202
URL: https://www.wjgnet.com/2218-4333/full/v2/i5/195.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i5.195